NEW/REVISED MATERIAL--EFFECTIVE DATE: 12/01/00

Section 319.4, Billing for Sodium Ferric Gluconate Complex in Sucrose Injection, adds a new section providing coverage, billing and payment instructions for sodium ferric gluconate complex in sucrose injection for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy.

Until a more specific HCPCS code is assigned, use J3490 to bill for this drug.

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted.
ESRD
BILLING PROCEDURES

Identifying Medicare Beneficiaries

Health Insurance Card and Other Evidence of Medicare Entitlement ........................................300
Identifying Health Insurance (HI) Claim Numbers ......................................................................304
  HICNs Assigned by the Railroad Retirement Board ..............................................................304.1
  All-Inclusive List of Potentially Valid RRB HICN ...............................................................304.2
  Change in Health Insurance Claim Numbers ........................................................................304.3
Reduction in Payment Due to P.L. 99-177 .................................................................................305
Part B Deductible .....................................................................................................................306
Part B Coinsurance ....................................................................................................................308
Determining How Much to Charge Patient Before Billing is Submitted for Part B Payment ....310

Beneficiary Request for Payment

Filing a Request for Payment .....................................................................................................312
  Request for Payment on Facility Record ..............................................................................312.2
  Time Limitation of Filing Claims for Dialysis Services ......................................................312.3
Execution of the Request for Payment .....................................................................................314
Scope of Waiver of Liability Provision ....................................................................................315
Form HCFA-1483, Provider Billing for Medical and Other Health Services .........................317
  General Information Concerning the Composite Rate ........................................................317.1
Beneficiary Selection, Form HCFA-382, for Home Dialysis Patients ....................................318
Epoetin(EPO) ............................................................................................................................319
  Payment for Drugs ..............................................................................................................319.1
  Blood and Blood Services Furnished in Independent Dialysis Facilities .........................319.2
  Coding for Adequacy of Hemodialysis ............................................................................319.3
  Billing for Sodium Ferric Gluconate Complex in Sucrose Injection ..................................319.4

Uniform Billing

Completion of Form HCFA-1450 by Independent Facilities for Home Dialysis Items and Services Billed Under the Composite Rate (Method I.) ........................................................................320
  Submitting Corrected Bills ..............................................................................................320.1
Completion of Form HCFA-1450, by Independent Facilities for Support Services for Method II Beneficiaries ........................................................................................................321
Clinical Laboratory Improvement Amendments (CLIA) ..............................................................322
# ESRD BILLING PROCEDURES

**Billing in Situations Where Medicare is Secondary Payor**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Preparation Where Medicare Benefits are Secondary to Employer Group Health Plans When Individuals are Entitled To Benefits Solely on the Basis of ESRD</td>
<td>323</td>
</tr>
<tr>
<td>Frequency of Billing</td>
<td>323.1</td>
</tr>
</tbody>
</table>

## Refunds

- Refund of Monies Incorrectly Collected | 324 |
- Return or Other Disposition of Monies Incorrectly Collected | 324.1 |
- Appropriate Time Limits Within Which Facility Must Dispose of Sums Incorrectly Collected | 324.2 |
- Former Facility | 324.3 |

## Credit Balance Reporting Requirements

- Submitting the HCFA-838 | 325.1 |
- Completing the HCFA-838 | 325.2 |
- Payment of Amount Owed Medicare | 325.3 |
- Records Supporting HCFA-838 Data | 325.4 |
- Provider-Based Home Health Agencies | 325.5 |
- Compliance with MSP Regulations | 325.7 |

- Exhibit I Medicare Credit Balance Report Certification | |
- Exhibit II Medicare Credit Balance Report (HCFA-838) | |

## Protests and Appeals

- Facility Protests of Payment Determination | 326 |
- Beneficiary Appeals (Part B) | 328 |
- Reopening and Revision of Medicare Claims Decision | 330 |

## Retention of Records

- Retention of Health Insurance Records | 332 |
- Destruction of Health Insurance Records | 332.1 |

## Claims Processing Timeliness Requirements

- Claims Processing Timeliness | 333 |
- Pneumococcal Pneumonia, Influenza Virus and Hepatitis B Vaccines | 334 |
- Exhibits | 399 |
If these codes are sufficient to describe the services provided by blood banks in your area, use the codes in billing. However, if these codes do not describe the services you are billing for, ask your intermediary to furnish the appropriate codes.

For supplies, use revenue code 270. Your intermediary establishes local codes for blood administration sets and filters and determines reasonable charge amounts for you.

### 319.3 Coding for Adequacy of Hemodialysis

#### A. General
All hemodialysis claims must indicate the most recent Urea Reduction Ratio (URR) for the dialysis patient. Code all claims using HCPCS code 90999 along with the appropriate G modifier listed in section B.

#### B. Billing Requirements
Claims for dialysis treatments must include the adequacy of dialysis data as measured by URR. Dialysis facilities must monitor the adequacy of dialysis treatments monthly for facility patients. Home hemodialysis and peritoneal dialysis patients may be monitored less frequently, but not less than quarterly.

HCPCS code 90999 (unlisted dialysis procedure, inpatient or outpatient) must be reported in field location 44 for all bill types 72X. Attach the appropriate G-modifier in field location 44 (HCPCS/RATES), for patients that received seven or more dialysis treatments in a month. Continue to report revenue codes 820, 821, 825, and 829 in field location 43.

- **G1** Most recent URR of less than 60%
- **G2** Most recent URR of 60% to 64.9%
- **G3** Most recent URR of 65% to 69.9%
- **G4** Most recent URR of 70% to 74.9%
- **G5** Most recent URR of 75% or greater

For patients that have received dialysis 6 days or less in a month, use the following modifier:

- **G6** ESRD patient for whom less than seven dialysis sessions have been provided in a month.

The techniques to be used to draw the pre- and post-dialysis blood urea Nitrogen samples are listed in the National Kidney Foundation Dialysis Outcomes Quality Initiative Clinical Practice Guidelines for Hemodialysis Adequacy, Guideline 8, Acceptable Methods for BUN sampling, New York, National Kidney Foundation, 1997, pp 53 - 60.

### 319.4 Billing for Sodium Ferric Gluconate Complex in Sucrose Injection

#### A. General
Iron deficiency is a common condition in end stage renal disease (ESRD) patients undergoing hemodialysis. Iron is a critical structural component of hemoglobin, a key protein found in normal red blood cells (RBCs) which transports oxygen. Without this important building block, anemic patients experience difficulty in restoring adequate, healthy RBC (hematocrit) levels. Clinical management of iron deficiency involves treating patients with iron replacement products while they undergo hemodialysis.

#### B. Billing Requirements
For claims with dates of service on or after December 1, 2000, sodium ferric gluconate complex in sucrose injection is covered by Medicare for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy. Payment is made at 95% average wholesale price (AWP). Deductible and coinsurance apply.

Bill on Form HCFA-1450 or electronic equivalent.
C. Applicable Bill Types.--The appropriate bill types are 13X, 72X, 82X and 85X.

When utilizing the UB-92 flat file use record type 40 to report bill type. Record type (Field No. 1), sequence number (Field No. 2), patient control number (Field No. 3), and type of bill (Field No. 4) are required. When utilizing the hard copy UB-92 (Form-1450) report the applicable bill type in Form Locator (FL) 4 “Type of Bill.” When utilizing the Medicare A 837 Health Care Claim version 3051 implementations 3A.01 and 1A.C1, report the applicable bill type in 2-130-CLM01, CLM05-01, and CLM05-03.

D. Revenue Code Reporting.--Report revenue code 633. When utilizing the UB-92 flat file use record type 61, Revenue Code (Field No. 5). When utilizing the hard copy UB-92, report the revenue code in FL 42 “Revenue Code.” When utilizing the Medicare A 837 Health Care Claim version 3051 implementations 3A.01 and 1A.C1, report the applicable revenue code in 2-395-SV201.

E. HCPCS Reporting.--Until a specific code for sodium ferric gluconate complex in sucrose injection is developed, report HCPCS code J3490 (Unclassified drugs). When utilizing the UB-92 flat file use record type 61, HCPCS code (Field No. 6) to report HCPCS code. When utilizing the hard copy UB-92 report the HCPCS code in FL 44 “HCPCS/Rates.” When utilizing the Medicare A 837 Health Care Claim version 3041 implementations 3A.01 and 1A.C1, report the HCPCS/CPT in 2-395-SV202-02.